Quintiles, Quest Diagnostics in clinical trials JV; Cerulean raising $50M;

@FierceBiotech: Skincare startup bags $50M to get its acne drug into Phase III. Article | Follow @FierceBiotech

@JohnCFierce: Merck ties up with tiny Syndax on a 'breakthrough' cancer combo. News | Follow @JohnCFierce

@DamianFierce: This could be the lingering effects of watching Going Clear, but doesn't Jadenu sound like an evil space lord? Novartis' release | Follow @DamianFierce

> Quintiles ($Q) and Quest Diagnostics ($DGX) are pooling their clinical trials laboratory operations into a new joint venture. Together they would have brought in $575 million last year, says Quintiles. Release

> Cerulean Pharma ($CERU) is selling $50 million in shares. Release

Medical Device News

@FierceMedDev: Medical device cybersecurity expert says better 'cybersecurity hygiene' needed. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: Philips brings in former Hologic CEO to head imaging biz in ongoing HealthTech revamp. Article | Follow @StacyALawrence

@VarunSaxena2: Japanese researchers study carbon nanotubes with drug delivery applications. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: $PHG sold its lighting business for $2.8B. Bloomberg article | Follow @EmilyWFierce

> VA starts trial of mobile app to help manage PTSD symptoms. Story

> Philips sells LED, automotive lighting for almost $3B, readies to reinvest in HealthTech. Article

> Olympus settles accounting scandal as it struggles to address duodenoscope difficulties. Report

Pharma News

@FiercePharma: ICYMI earlier: $GSK finally seals U.K. Bexsero deal for £20 per dose. FierceVaccines story | Follow @FiercePharma

@EricPFierce: ICYMI last week from FiercePharmaManufacturing: IPCA says FDA bans will have little sales impact. Didn't Wockhardt make that claim before its profits sank? More | Follow @EricPFierce

@CarlyHFierce: New fantasy: An Invokana/Vimizim final. Tell me that doesn't sound like a Halloween dream come true. Make it happen, people. | Follow @CarlyHFierce

> Watch out, Pomalyst: Amgen gets quick FDA review for lucrative new Kyprolis use. Story

> Judge tosses Abilify kickback claims, but puts BMS on notice for firing whistleblowers. Article

> Abbott puts one-third of its $6B Mylan stake on the block. Report

Drug Delivery News

> Genisphere boasts preclinical success of 3DNA platform for cataract complications. Report

> Columbia Labs picks up multidrug intravaginal ring created at MIT and MGH. More

> Researchers convert microbubbles to even smaller nanobubbles using ultrasound. Item

> Japanese researchers studying carbon nanotubes with drug delivery applications. Story

> Novan receives $50M in support of drug delivery tech to treat acne, HPV. Article

Pharma Manufacturing News

> Mylan recalling two injectable drugs made in India. Report

> Federal authorities raid Internet pharmacy operator CanadaDrugs.com. More

> Fujifilm expands in U.S. again with deal for stem cell producer. Story

> Roche's Genentech investing $125M in Oregon plant. News

> Sanofi vaccine plant in Canada again producing ImmuCyst bladder drug. Article

Pharma Asia News

> Japan pharma market on track for $80B mark by 2020, but obstacles seen. News

> Indian company says compulsory license use has cost country $10B in potential investments. Report

> China puts stem-cell clinical trial regulation in play with draft for comment. More

> 'Japanese NIH' launches April 1 with focus on devices and drugs. Story

> Chi-Med's fruquintinib meets metastatic colorectal cancer Phase II primary endpoint. Article


Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.